Banque Transatlantique SA Invests $270,000 in Gilead Sciences, Inc. $GILD

Key Points

• Banque Transatlantique SA has invested approximately $270,000 in Gilead Sciences by acquiring 2,611 shares as indicated in their recent SEC filing.
• Gilead Sciences reported a quarterly earnings of $2.01 EPS, exceeding analysts' expectations, with a revenue of $7.08 billion for the quarter.
• The company announced a quarterly dividend of $0.79 per share, translating to an annual yield of 2.8%, which will be paid on September 29th.

Banque Transatlantique SA bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,611 shares of the biopharmaceutical company's stock, valued at approximately $270,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. AQR Capital Management LLC lifted its stake in Gilead Sciences by 2.8% during the first quarter. AQR Capital Management LLC now owns 1,864,670 shares of the biopharmaceutical company's stock valued at $207,370,000 after purchasing an additional 51,116 shares during the last quarter. Ariel Investments LLC lifted its stake in Gilead Sciences by 7.7% during the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock valued at $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Atalanta Sosnoff Capital LLC lifted its stake in Gilead Sciences by 10.3% during the first quarter. Atalanta Sosnoff Capital LLC now owns 2,921 shares of the biopharmaceutical company's stock valued at $327,000 after purchasing an additional 273 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in Gilead Sciences by 6.4% during the first quarter. Advisors Asset Management Inc. now owns 239,934 shares of the biopharmaceutical company's stock valued at $26,885,000 after purchasing an additional 14,358 shares during the last quarter. Finally, Aprio Wealth Management LLC lifted its stake in Gilead Sciences by 57.0% during the first quarter. Aprio Wealth Management LLC now owns 12,189 shares of the biopharmaceutical company's stock valued at $1,366,000 after purchasing an additional 4,423 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares in the company, valued at $18,977,838.30. This represents a 1.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,000 shares of company stock worth $9,371,330. Company insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. UBS Group boosted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a report on Friday, July 25th. Finally, Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Down 0.1%

Gilead Sciences stock traded down $0.09 during trading hours on Wednesday, hitting $115.67. The company had a trading volume of 1,156,451 shares, compared to its average volume of 8,094,844. The firm has a market capitalization of $143.53 billion, a P/E ratio of 23.07, a price-to-earnings-growth ratio of 0.79 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The firm's fifty day moving average is $113.77 and its 200-day moving average is $109.99. Gilead Sciences, Inc. has a fifty-two week low of $79.64 and a fifty-two week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.